HeartSciences (NASDAQ:HSCS) Announces Quarterly Earnings Results

HeartSciences (NASDAQ:HSCS) released its quarterly earnings results on Monday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14), FiscalAI reports. The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.10 million.

HeartSciences Stock Down 2.8%

Shares of NASDAQ:HSCS opened at $3.44 on Wednesday. HeartSciences has a fifty-two week low of $1.63 and a fifty-two week high of $4.35. The firm’s 50 day moving average price is $2.70 and its 200 day moving average price is $2.39. The stock has a market cap of $13.42 million, a price-to-earnings ratio of -1.07 and a beta of 1.85.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HSCS. Wall Street Zen raised HeartSciences to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, HeartSciences currently has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.